Daily Stock Opinions and Ratings

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Opinions

Jordan ZinbergCloudMDDOC.VHOLDFeb 03, 2023

Tele-health company.
Has sold shares. Very high valuations.
Path to profitability slower than expected.
Recently selling assets.
Not sure path to profitability.

Jordan Zinberg

Unlock Rating

$0.22

Stock price when the opinion was issued

$0.04

As of Jul 10, 2024. Market Open.

Healthcare

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

DON'T BUY

Did very well during the pandemic, a market darling then. But their acquisitions didn't make sense to him and they have caught up with them with poor integration. The hype is over and shares have plunged since 2020.

WATCH

Interesting story, 70M market cap. Took goodwill impairment of 84M, as a result of acquisitions. Follows it, great business model. Difficult investing environment right now. (Analysts’ price target is $0.48)

PAST TOP PICK

(A Top Pick Sep 20/21, Down 76%) Whole sector decimated. One of the fastest-growing healthcare technology solutions providers. Still integrating acquisitions. Positive EBITDA has been pushed out. Management turnover. Well managed, but a show-me story.

TRADE

The industry is trading at a discount to its U.S. peers. There are other similar ones to own as well. It is good but he wants to see a couple of quarters with profitability.

PAST TOP PICK

(A Top Pick Jun 23/21, Down 71%) Fastest growing health technology provider. Sector had been hit very hard with market selloff. Recently signed large contract with Sunlife. Process integrating large number of acquisitions. Recent CEO, Chairman and management resignations is cause for concern.

PAST TOP PICK

(A Top Pick Jun 29/21, Down 77%) Brutal in the small cap area. Still likes it, but got stopped out. Beat expectations, business doing well. Moving forward with plans. This is why it's important to use stops, especially with small caps.

BUY

A fast-growing telehealth company and are pushing hard into enterprise health solutions by offering a one-stop patient approach to the primary care and mental health sectors. They are integrating several acquisitions. They are guiding to an EBITDA of $10 million this year which they could surpass. This sector has been almost left for dead, but the digital revolution in health has just begun so now is the time to enter it.

BUY

One of the fastest healthcare technology companies. Expanding into enterprise health solutions space. Expecting strong financial results in 2022. Low stock price presenting good buying opportunity.

STRONG BUY

One of two he owns in the health care sector. Digitization within health care has only just begun. The last quarter beat expectations. They announced a large deal with Sun Life on mental health coaching. This alone could be $40 million in annual revenues. Things are going in the right direction and will exceed expectations next year. A very good entry point here.

BUY

Pre-announced today that revenues will be higher than forecast. Encouraging, as there's significant organic growth in addition to acquisitions. Likes the strategy. Will probably be one of the few telehealth winners. Lots of strings to their bow. Good time to buy. Sky's the limit on target prices for this sector. Good long-term hold.

BUY ON WEAKNESS

Small caps have seen some correction, but the underlying fundamentals are growing. The business continues to move forward. What was considered telemedicine has now extended out to more services, such as employer plans. Top line growth is around 10% per quarter. They are profitable and has large cash positions to make acquisitions. Trading at half the valuation of WELL.

BUY

Exciting play on telemedicine. Entire sector is pricey, but good upside opportunity if the trends continue. The whole concept makes a lot of sense. Good sector to have some exposure to. He owns a small position.

TOP PICK

It is one of the fastest growing healthcare solutions providers. They made a series of very targeted acquisitions which they are integrating. A quality company with quality assets. (Analysts’ price target is $4.19)

BUY

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. Revenue grew by 461% year over year. However, EPS missed estimates. It is growing extremely fast and organic growth is forecasted to be driven by partner relationships. The balance sheet is growing rapidly and top-line growth should outpace operating expenses. Unlock Premium - Try 5i Free

Most Recent Experts

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Gordon Reid

GoodReid Investment Counsel

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Jordan ZinbergCloudMDDOC.VHOLDFeb 03, 2023

You might be interested:

CloudMD(DOC.V)

CloudMD(DOC.V)

CloudMD(DOC.V)

CloudMD(DOC.V)

CloudMD(DOC.V)

CloudMD(DOC.V)

CloudMD(DOC.V)

CloudMD(DOC.V)

CloudMD(DOC.V)

CloudMD(DOC.V)

CloudMD(DOC.V)

CloudMD(DOC.V)

CloudMD(DOC.V)

CloudMD(DOC.V)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Joe Terranova

Stephen Weiss, Founder, Short Hills Capital Partners

Rob Sechan, Managing Partner, New Edge Capital

Gordon Reid

Jim Cramer - Mad Money